Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dr. Reddy's Laboratories Limited (RDY) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Dr. Reddy's files reports such as Form 6-K with the Securities and Exchange Commission, providing investors with access to financial results, board and corporate actions, and other information furnished under its home-country requirements.
Key filing types for Dr. Reddy's include periodic Form 6-K submissions that often attach consolidated IFRS financial statements, segment data for Global Generics and Pharmaceutical Services and Active Ingredients (PSAI), and management commentary on revenue trends, R&D spending and regional performance. These filings can also include intimations regarding board meetings, corporate actions and other material updates first disclosed in India.
For a pharmaceutical manufacturer active in APIs, generics, branded generics, biosimilars and OTC products, SEC filings are a primary source for understanding segment performance, geographic mix and investment in R&D. Investors can use them to track how Dr. Reddy's generics and biosimilars portfolios evolve, how collaborations and acquisitions contribute to results, and how the company allocates capital across regions and product categories.
On Stock Titan, each new RDY filing from EDGAR is captured and organized chronologically. AI-powered summaries help explain the main points of lengthy documents, highlighting items such as revenue movements, margin changes, R&D focus areas and notable regulatory or ESG disclosures. Users can quickly scan these summaries before diving into the full text of a 6-K or related exhibits.
In addition to financial information, this page can surface filings that relate to governance, risk and compliance, complementing press releases about inspections, recalls or ESG recognitions. Together, these documents provide a structured view of Dr. Reddy's regulatory footprint in the U.S. and support deeper analysis of the RDY stock for research-oriented investors.
Form 6-K overview
Dr. Reddy’s Laboratories Limited (RDY) filed a Form 6-K with the SEC dated 23 June 2025. The submission contains one exhibit—Exhibit 99.1: “Intimation regarding Board Meeting.” No financial statements, earnings figures, or major transactional details accompany the notice. The company confirms it files annual reports on Form 20-F and is not claiming the Rule 12g3-2(b) exemption. The filing is signed by Company Secretary K Randhir Singh from the Hyderabad headquarters.
Because the document simply alerts investors that a board meeting will be convened, without disclosing the meeting date, agenda, or potential resolutions, it offers no material information likely to impact valuation or strategy.
Dr. Reddy’s Laboratories Limited (NYSE: RDY) filed a routine Form 6-K with the U.S. SEC dated 20 June 2025. The submission contains only the cover page, signature page and an index showing a single exhibit—Exhibit 99.1: “Intimation dated June 20, 2025.” The actual exhibit text and any related financial, operational or strategic information are not included in the material provided for review. Therefore, no financial results, guidance updates, transactions, regulatory actions or other material events can be assessed from this filing alone.
The filing confirms that RDY continues to report under Form 20-F for annual statements and that this 6-K is being furnished—not filed—for SEC purposes, preserving safe-harbor protections. The document was signed by Company Secretary K Randhir Singh.
Because the substantive Exhibit 99.1 content is unavailable, the investor impact of this 6-K cannot be determined based on the information supplied.
On June 20, 2025, Dr. Reddy’s Laboratories Limited (NYSE: RDY) furnished a routine Form 6-K to the U.S. Securities and Exchange Commission. The filing affirms that the company continues to submit its annual reports on Form 20-F and is not relying on the Rule 12g3-2(b) exemption. The sole attachment is Exhibit 99.1 – “Intimation dated June 20, 2025.” The document was signed by Company Secretary K Randhir Singh. No financial statements, earnings figures, or descriptions of material transactions accompany this report, indicating that the submission is administrative in nature and unlikely to affect the company’s financial outlook or valuation.
FAQ
What is the current stock price of Dr Reddys Labs (RDY)?
What is the market cap of Dr Reddys Labs (RDY)?
